Global Schizophrenia Therapeutic Market Drivers
The global schizophrenia therapeutic market size is expected to expand, owing to increasing prevalence of schizophrenia. In 2018, World Health Organization (WHO) reported that over 23 million patients were affected by schizophrenia worldwide. Furthermore, increasing approvals of therapies with second generation antipsychotic drugs such as Risperidone, Paliperidone, Olanzapine, and Lurasidone, which have less side effects is also expected to drive the global schizophrenia therapeutic market revenue. For instance, in 2015, the U.S. Food and Drugs Administration (FDA) approved Vraylar (Cariprazine), which was tested on 1,750 patients. The drug showed effective reduction of symptoms in schizophrenia in less time.
Global Schizophrenia Therapeutic Restraints
The common negligence and stigma regarding schizophrenia is one of the major restraining factors for hampering the schizophrenia therapeutic market growth. For instance, in 2018, the Schizophrenia and Related Disorders Alliance of America (SARDAA) reported that around 50% of people diagnosed with schizophrenia do not receive treatment, owing to negligence for mental health.
Moreover, the side effects caused by antipsychotics such as weight gain, dizziness, restlessness, nausea, blurred vision, low blood pressure, seizures, and constipation can also be negative growth rendering factor for the global schizophrenia therapeutic market revenue. For instance, according to National Centre for Biotechnology Information (NCBI) 2017 findings, obesity is affecting 15%-72% patients, 12% of patients are suffering from diabetes, and the prevalence of constipation is 39% in schizophrenic patients. Consumption of antipsychotics may also lead to sudden cardiac death and ventricular arrhythmia.
Schizophrenia Therapeutic Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients